Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

This article is part of the supplement: Basic science, rationale, background and future of denosumab: a RANK ligand inhibitor

Highly Accessed Review

Clinical development of anti-RANKL therapy

Edward M Schwarz* and Christopher T Ritchlin

Arthritis Research & Therapy 2007, 9(Suppl 1):S7  doi:10.1186/ar2171

Accesses  

  • Last 30 days: 53 accesses
  • Last 365 days: 747 accesses
  • All time: 9253 accesses